Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.67
EBS's Cash to Debt is ranked higher than
57% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. EBS: 0.67 )
EBS' s 10-Year Cash to Debt Range
Min: 0.52   Max: No Debt
Current: 0.67

Equity to Asset 0.58
EBS's Equity to Asset is ranked higher than
67% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. EBS: 0.58 )
EBS' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.81
Current: 0.58

0.33
0.81
F-Score: 3
Z-Score: 2.73
M-Score: -2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.79
EBS's Operating margin (%) is ranked higher than
85% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. EBS: 6.79 )
EBS' s 10-Year Operating margin (%) Range
Min: -0.8   Max: 48.09
Current: 6.79

-0.8
48.09
Net-margin (%) 3.84
EBS's Net-margin (%) is ranked higher than
84% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. EBS: 3.84 )
EBS' s 10-Year Net-margin (%) Range
Min: -1.22   Max: 46.34
Current: 3.84

-1.22
46.34
ROE (%) 2.77
EBS's ROE (%) is ranked higher than
84% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. EBS: 2.77 )
EBS' s 10-Year ROE (%) Range
Min: 5.33   Max: 875.86
Current: 2.77

5.33
875.86
ROA (%) 1.61
EBS's ROA (%) is ranked higher than
85% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. EBS: 1.61 )
EBS' s 10-Year ROA (%) Range
Min: -2.18   Max: 159.68
Current: 1.61

-2.18
159.68
ROC (Joel Greenblatt) (%) 5.91
EBS's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. EBS: 5.91 )
EBS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.79   Max: 69.62
Current: 5.91

9.79
69.62
Revenue Growth (%) -1.10
EBS's Revenue Growth (%) is ranked higher than
75% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. EBS: -1.10 )
EBS' s 10-Year Revenue Growth (%) Range
Min: -1.1   Max: 31.4
Current: -1.1

-1.1
31.4
EBITDA Growth (%) -11.30
EBS's EBITDA Growth (%) is ranked higher than
71% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. EBS: -11.30 )
EBS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.9
Current: -11.3

0
20.9
EPS Growth (%) -18.80
EBS's EPS Growth (%) is ranked higher than
69% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. EBS: -18.80 )
EBS' s 10-Year EPS Growth (%) Range
Min: -26.7   Max: 61.7
Current: -18.8

-26.7
61.7
» EBS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

EBS Guru Trades in Q3 2013

John Rogers 59,600 sh (+116.73%)
Steven Cohen 853,748 sh (+60.88%)
Ken Fisher 434,195 sh (+10.32%)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons 597,511 sh (-17.45%)
» More
Q4 2013

EBS Guru Trades in Q4 2013

John Rogers 122,650 sh (+105.79%)
Steven Cohen 913,816 sh (+7.04%)
Jim Simons 563,611 sh (-5.67%)
Ken Fisher 399,595 sh (-7.97%)
» More
Q1 2014

EBS Guru Trades in Q1 2014

Paul Tudor Jones 20,743 sh (New)
John Burbank 7,987 sh (New)
Joel Greenblatt 258,760 sh (New)
Jim Simons 762,898 sh (+35.36%)
John Rogers Sold Out
Ken Fisher 398,670 sh (-0.23%)
Steven Cohen 401,847 sh (-56.03%)
» More
Q2 2014

EBS Guru Trades in Q2 2014

Paul Tudor Jones 29,400 sh (+41.73%)
Ken Fisher 468,757 sh (+17.58%)
John Burbank Sold Out
Joel Greenblatt 221,928 sh (-14.23%)
Jim Simons 607,511 sh (-20.37%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$20.42 - $26.78 $ 22.28-4%0
Joel Greenblatt 2014-03-31 New Buy0.1%$22.85 - $28.09 $ 22.28-12%258760
John Burbank 2014-03-31 New Buy0.01%$22.85 - $28.09 $ 22.28-12%7987
Joel Greenblatt 2013-03-31 Sold Out 0.14%$13.95 - $16.9 $ 22.2842%0
Joel Greenblatt 2012-12-31 New Buy0.14%$12.91 - $16.09 $ 22.2852%147099
Joel Greenblatt 2011-12-31 Sold Out 0.08%$15.43 - $19.64 $ 22.2828%0
Joel Greenblatt 2011-06-30 Reduce -20.74%0.05%$20.66 - $24.98 $ 22.28-4%26620
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 64.40
EBS's P/E(ttm) is ranked higher than
88% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 64.40 )
EBS' s 10-Year P/E(ttm) Range
Min: 6.72   Max: 71.97
Current: 64.4

6.72
71.97
P/B 1.71
EBS's P/B is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. EBS: 1.71 )
EBS' s 10-Year P/B Range
Min: 0.84   Max: 3.82
Current: 1.71

0.84
3.82
P/S 2.38
EBS's P/S is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. EBS: 2.38 )
EBS' s 10-Year P/S Range
Min: 0.81   Max: 4.34
Current: 2.38

0.81
4.34
PFCF 63.66
EBS's PFCF is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 63.66 )
EBS' s 10-Year PFCF Range
Min: 5.52   Max: 748.33
Current: 63.66

5.52
748.33
EV-to-EBIT 38.78
EBS's EV-to-EBIT is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 38.78 )
EBS' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 43.5
Current: 38.78

3.3
43.5
Shiller P/E 27.28
EBS's Shiller P/E is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 27.28 )
EBS' s 10-Year Shiller P/E Range
Min: 13.29   Max: 34.71
Current: 27.28

13.29
34.71
Current Ratio 4.52
EBS's Current Ratio is ranked higher than
74% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. EBS: 4.52 )
EBS' s 10-Year Current Ratio Range
Min: 1.22   Max: 5.57
Current: 4.52

1.22
5.57
Quick Ratio 3.66
EBS's Quick Ratio is ranked higher than
71% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. EBS: 3.66 )
EBS' s 10-Year Quick Ratio Range
Min: 0.76   Max: 5.17
Current: 3.66

0.76
5.17

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.58
EBS's Price/Tangible Book is ranked higher than
91% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. EBS: 2.58 )
EBS' s 10-Year Price/Tangible Book Range
Min: 0.88   Max: 3.92
Current: 2.58

0.88
3.92
Price/DCF (Projected) 1.86
EBS's Price/DCF (Projected) is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 1.86 )
EBS' s 10-Year Price/DCF (Projected) Range
Min: 1.12   Max: 2.93
Current: 1.86

1.12
2.93
Price/Median PS Value 1.11
EBS's Price/Median PS Value is ranked higher than
83% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. EBS: 1.11 )
EBS' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 2.07
Current: 1.11

0.39
2.07
Price/Graham Number 2.66
EBS's Price/Graham Number is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EBS: 2.66 )
EBS' s 10-Year Price/Graham Number Range
Min: 0.51   Max: 2.69
Current: 2.66

0.51
2.69
Earnings Yield (Greenblatt) 2.60
EBS's Earnings Yield (Greenblatt) is ranked higher than
65% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. EBS: 2.60 )
EBS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 30.2
Current: 2.6

2.3
30.2
Forward Rate of Return (Yacktman) 5.19
EBS's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. EBS: 5.19 )
EBS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.7   Max: 111.4
Current: 5.19

-14.7
111.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ER4.Germany
Emergent BioSolutions Inc. was incorporated as BioPort Corporation under the laws of Michigan in May 1998. In June 2004, it completed a corporate reorganization in which Emergent BioSolutions Inc., a Delaware corporation formed in December 2003, issued shares of class A common stock to stockholders of BioPort in exchange for an equal number of outstanding shares of common stock of BioPort. As a result of this reorganization, BioPort became the Company's wholly owned subsidiary. It subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Emergent BioSolutions Inc. is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and commercial. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's commercial segment focuses on vaccines and therapeutics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Its product candidates in this segment include a typhoid vaccine, a tuberculosis vaccine, a hepatitis B therapeutic vaccine and a chlamydia vaccine. The Company faces competition with respect to BioThrax, its current product candidates from major pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research institutions that conduct research, seek patent protection and establish collaborative arrangemen
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 25,000 Shares Apr 29 2010 

More From Other Websites
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal Sep 10 2014
Emergent BioSolutions Awarded Contract to Develop a Dry Formulation of NuThrax, a Next Generation... Sep 08 2014
Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate Aug 20 2014
Morphosys AG On License Agreement With Emergent To Co-Develop And Commercialize Prostate Cancer Drug... Aug 20 2014
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 20 2014
MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014
Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014
MorphoSys and Emergent BioSolutions Sign License Agreement to Co-Develop and Commercialize Prostate... Aug 19 2014
EMERGENT BIOSOLUTIONS INC. Financials Aug 15 2014
Emergent BioSolutions Misses on Earnings, Ups Revenue View Aug 11 2014
U.S. emergency labs ready to work on Ebola drugs if asked Aug 10 2014
US labs on standby to start work on Ebola drug Aug 10 2014
U.S. Government Exercises Contract Options Valued at $18.9M for Emergent BioSolutions' Vaccinia... Aug 08 2014
EMERGENT BIOSOLUTIONS INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
Emergent BioSolutions Inc Earnings Call scheduled for 5:00 pm ET today Aug 07 2014
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014 Aug 07 2014
Q2 2014 Emergent BioSolutions Inc. Earnings Release - After Market Close Aug 07 2014
Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin... Aug 07 2014
Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? Aug 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK